Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126844161 | 12684416 | 1 | I | 20160818 | 20160825 | 20160825 | EXP | CA-AMGEN-CANSP2016109250 | AMGEN | 0.00 | F | Y | 0.00000 | 20160825 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126844161 | 12684416 | 1 | PS | ENBREL | ETANERCEPT | 1 | Subcutaneous | 50 MG, QWK | U | 103795 | 50 | MG | UNKNOWN FORMULATION | /wk | |||||
| 126844161 | 12684416 | 2 | SS | ACTEMRA | TOCILIZUMAB | 1 | Subcutaneous | UNK | 0 | ||||||||||
| 126844161 | 12684416 | 3 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | UNK | 0 | ||||||||||
| 126844161 | 12684416 | 4 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | 40 MG, Q2WK | 0 | 40 | MG | QOW | |||||||
| 126844161 | 12684416 | 5 | SS | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | Unknown | 20 MG, QD | 0 | 20 | MG | TABLET | QD | ||||||
| 126844161 | 12684416 | 6 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | 20 MG, QWK | 0 | 20 | MG | /wk | |||||||
| 126844161 | 12684416 | 7 | SS | ORENCIA | ABATACEPT | 1 | Intravenous (not otherwise specified) | 750 MG, Q4WK | 0 | 750 | MG | ||||||||
| 126844161 | 12684416 | 8 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | 5 MG/KG, Q8WK | 0 | 5 | MG/KG | ||||||||
| 126844161 | 12684416 | 9 | C | XELJANZ | TOFACITINIB CITRATE | 1 | Unknown | 0 | |||||||||||
| 126844161 | 12684416 | 10 | C | CIMZIA | CERTOLIZUMAB PEGOL | 1 | Subcutaneous | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126844161 | 12684416 | 1 | Rheumatoid arthritis |
| 126844161 | 12684416 | 2 | Product used for unknown indication |
| 126844161 | 12684416 | 4 | Product used for unknown indication |
| 126844161 | 12684416 | 5 | Product used for unknown indication |
| 126844161 | 12684416 | 6 | Rheumatoid arthritis |
| 126844161 | 12684416 | 7 | Rheumatoid arthritis |
| 126844161 | 12684416 | 8 | Product used for unknown indication |
| 126844161 | 12684416 | 9 | Product used for unknown indication |
| 126844161 | 12684416 | 10 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126844161 | 12684416 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126844161 | 12684416 | Arthropathy | |
| 126844161 | 12684416 | Drug ineffective | |
| 126844161 | 12684416 | Gait disturbance |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |